Abivax S.A Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

Media coverage

• Title	Abivax S.A Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
  Media name/outlet	Global Round Up - Bullish & Bearish Signals
  Country/Territory	United States
  Date	5/10/24
  Persons	Marla Dubinsky